Feb 05, 2025 |
|
Ben Chaiken |
Mizuho Securities |
$263.00 |
$258.74 |
1.6%
|
Hilton downgraded to Neutral from Outperform at Mizuho
|
Feb 05, 2025 |
|
Arun Viswanathan |
RBC Capital |
$47.00 |
$55.78 |
-15.7%
|
FMC downgraded to Sector Perform from Outperform at RBC Capital
|
Feb 05, 2025 |
|
Suji Desilva |
Roth Capital |
$140.00 |
$119.50 |
17.2%
|
AMD price target lowered to $140 from $200 at Roth MKM
|
Feb 05, 2025 |
|
Terence Flynn |
Morgan Stanley |
$106.00 |
$90.74 |
16.8%
|
Merck price target lowered to $106 from $113 at Morgan Stanley
|
Feb 04, 2025 |
|
Michael Ng |
Goldman Sachs |
$60.00 |
$54.64 |
9.8%
|
Fox Corp. price target raised to $60 from $57 at Goldman Sachs
|
Feb 04, 2025 |
|
Lina Yan |
HSBC |
$32.40 |
$32.08 |
1.0%
|
H World downgraded to Hold from Buy at HSBC
|
Feb 04, 2025 |
|
Laura Champine |
Loop Capital Markets |
$250.00 |
$263.59 |
-5.2%
|
Loop starts Royal Caribbean at Hold with demand recovery priced in
|
Feb 04, 2025 |
|
Laura Champine |
Loop Capital Markets |
$55.00 |
$51.45 |
6.9%
|
Loop initiates cruise lines with Viking only Buy on growth prospects
|
Feb 04, 2025 |
|
Andrew Lazar |
Barclays |
$85.00 |
$74.92 |
13.5%
|
BellRing Brands price target raised to $85 from $79 at Barclays
|
Feb 04, 2025 |
|
Mark Mahaney |
UBS |
$700.00 |
$621.77 |
12.6%
|
Spotify target raised to $700 at Evercore after 'very impressive' Q4 results
|
Feb 04, 2025 |
|
Erin Wright |
Morgan Stanley |
$243.00 |
$172.24 |
41.1%
|
Librela U.S. label update 'better than feared' for Zoetis, says Morgan Stanley
|
Feb 04, 2025 |
|
Ivan Feinseth |
Tigress Financial |
$32.00 |
$24.25 |
32.0%
|
AT&T price target raised to $32 from $30 at Tigress Financial
|
Feb 04, 2025 |
|
Michael Diana |
Maxim Group |
$28.00 |
$23.89 |
17.2%
|
First Savings Financial Group price target lowered to $28 from $32 at Maxim
|
Feb 04, 2025 |
|
Zevra Therapeutics to $ |
Guggenheim |
$21.00 |
$8.13 |
158.3%
|
Zevra Therapeutics price target raised to $21 from $20 at Guggenheim
|
Feb 04, 2025 |
|
Kristina Ruggeri |
Argus Research |
$148.00 |
$125.17 |
18.2%
|
Cardinal Health price target raised to $148 from $145 at Argus
|
Feb 04, 2025 |
|
Steven Forbes |
Guggenheim |
$42.00 |
$38.62 |
8.8%
|
Chewy price target raised to $42 from $36 at Guggenheim
|
Feb 04, 2025 |
|
Joseph Moore |
Morgan Stanley |
$58.00 |
$52.60 |
10.3%
|
Microchip price target lowered to $58 from $71 at Morgan Stanley
|
Feb 04, 2025 |
|
Jaeson Schmidt |
Lake Street |
$30.00 |
$26.42 |
13.6%
|
Napco Security price target lowered to $30 from $41 at Lake Street
|
Feb 04, 2025 |
|
John Freeman |
Raymond James |
$58.00 |
$48.70 |
19.1%
|
Viper Energy price target lowered to $58 from $64 at Raymond James
|
Feb 04, 2025 |
|
Joseph Moore |
Morgan Stanley |
$147.00 |
$119.50 |
23.0%
|
AMD price target lowered to $147 from $158 at Morgan Stanley
|
Feb 04, 2025 |
|
Gil Luria |
D.A. Davidson |
$105.00 |
$103.83 |
1.1%
|
Palantir price target raised to $105 from $47 at DA Davidson
|
Feb 04, 2025 |
|
Savanthi Syth |
Raymond James |
$5.00 |
$2.24 |
123.2%
|
Azul price target lowered to $5 from $6 at Raymond James
|
Feb 04, 2025 |
|
Farooq Hamed |
Raymond James |
$105.00 |
$95.59 |
9.8%
|
Agnico Eagle price target raised to $105 from $97 at Raymond James
|
Feb 04, 2025 |
|
Kenneth Lee |
RBC Capital |
$27.00 |
$23.76 |
13.6%
|
Acadian Asset Management price target lowered to $27 from $33 at RBC Capital
|
Feb 04, 2025 |
|
Arun Viswanathan |
RBC Capital |
$120.00 |
$111.27 |
7.8%
|
PPG price target lowered to $120 from $128 at RBC Capital
|
Feb 04, 2025 |
|
Catherine Ramsey Schulte |
Robert W. Baird |
$54.00 |
$52.02 |
3.8%
|
Twist Bioscience price target raised to $54 from $48 at Baird
|
Feb 04, 2025 |
|
Peter Benedict |
Robert W. Baird |
$3.00 |
$2.17 |
38.2%
|
Leslie's price target lowered to $3 from $3.50 at Baird
|
Feb 04, 2025 |
|
Jeremy Hamblin |
Craig-Hallum |
$28.00 |
$26.42 |
6.0%
|
Napco Security downgraded to Hold from Buy at Craig-Hallum
|
Feb 04, 2025 |
|
Mehdi Hosseini |
Susquehanna |
$70.00 |
$64.44 |
8.6%
|
Rambus price target raised to $70 from $66 at Susquehanna
|
Feb 04, 2025 |
|
Christopher Stathoulopoulos |
Susquehanna |
$34.00 |
$30.79 |
10.4%
|
Southwest price target lowered to $34 from $38 at Susquehanna
|
Feb 04, 2025 |
|
Christopher Stathoulopoulos |
Susquehanna |
$130.00 |
$108.67 |
19.6%
|
United Airlines price target raised to $130 from $120 at Susquehanna
|
Feb 04, 2025 |
|
Benjamin Swinburne |
Morgan Stanley |
$11.00 |
$10.92 |
0.7%
|
Paramount price target raised to $11 from $10 at Morgan Stanley
|
Feb 04, 2025 |
|
Gregg Moskowitz |
Mizuho Securities |
$80.00 |
$103.83 |
-23.0%
|
Palantir price target raised to $80 from $44 at Mizuho
|
Feb 04, 2025 |
|
Vincent Andrews |
Morgan Stanley |
$28.00 |
$27.72 |
1.0%
|
Olin price target lowered to $28 from $31 at Morgan Stanley
|
Feb 04, 2025 |
|
Stephen Ju |
UBS |
$143.00 |
$130.74 |
9.4%
|
Airbnb price target raised to $143 from $142 at UBS
|
Feb 04, 2025 |
|
Anna Andreeva |
Piper Sandler |
$40.00 |
$37.29 |
7.3%
|
Steven Madden price target lowered to $40 from $45 at Piper Sandler
|
Feb 04, 2025 |
|
Frank Schiraldi |
Piper Sandler |
$30.00 |
$26.93 |
11.4%
|
Arrow Financial price target lowered to $30 from $32 at Piper Sandler
|
Feb 04, 2025 |
|
David Amsellem |
Piper Sandler |
$36.00 |
$30.93 |
16.4%
|
Collegium Pharmaceutical price target lowered to $36 from $37 at Piper Sandler
|
Feb 04, 2025 |
|
Brian McKenna |
JMP Securities |
$17.00 |
$15.10 |
12.6%
|
Blue Owl Capital price target raised to $17 from $16.50 at JMP Securities
|
Feb 04, 2025 |
|
Stephen Baxter |
Wells Fargo |
$341.00 |
$291.46 |
17.0%
|
Cigna price target lowered to $341 from $370 at Wells Fargo
|
Feb 04, 2025 |
|
Simon Yarmak |
Stifel Nicolaus |
$82.25 |
$70.62 |
16.5%
|
Equity Residential price target lowered to $82.25 from $85 at Stifel
|
Feb 04, 2025 |
|
Christine Cho |
Barclays |
$1.50 |
$1.17 |
28.2%
|
Blink Charging price target lowered to $1.50 from $3 at Barclays
|
Feb 04, 2025 |
|
David Strauss |
Barclays |
$285.00 |
$257.43 |
10.7%
|
General Dynamics price target lowered to $285 from $305 at Barclays
|
Feb 04, 2025 |
|
Matthew Akers |
Wells Fargo |
$205.00 |
$184.50 |
11.1%
|
Woodward price target raised to $205 from $193 at Wells Fargo
|
Feb 04, 2025 |
|
Aaron Rakers |
Wells Fargo |
$73.00 |
$64.44 |
13.3%
|
Rambus price target raised to $73 from $62 at Wells Fargo
|
Feb 04, 2025 |
|
Sam Reid |
Wells Fargo |
$82.00 |
$77.29 |
6.1%
|
Masco price target lowered to $82 from $85 at Wells Fargo
|
Feb 04, 2025 |
|
Duane Pfennigwerth |
Evercore ISI |
$330.00 |
$290.75 |
13.5%
|
Marriott upgraded to Outperform from In Line at Evercore ISI
|
Feb 04, 2025 |
|
Daniel Politzer |
Wells Fargo |
$285.00 |
$290.75 |
-2.0%
|
Marriott price target raised to $285 from $262 at Wells Fargo
|
Feb 04, 2025 |
|
Daniel Politzer |
Wells Fargo |
$240.00 |
$258.74 |
-7.2%
|
Hilton price target raised to $240 from $232 at Wells Fargo
|
Feb 04, 2025 |
|
Ryan Zimmerman |
BTIG |
$16.00 |
$10.51 |
52.2%
|
Treace Medical upgraded to Buy from Neutral at BTIG
|
Feb 04, 2025 |
|
Alex Scott |
Barclays |
$470.00 |
$341.72 |
37.5%
|
Everest Group price target raised to $470 from $461 at Barclays
|
Feb 04, 2025 |
|
Richard Hightower |
Barclays |
$46.00 |
$38.93 |
18.2%
|
NNN REIT price target lowered to $46 from $48 at Barclays
|
Feb 04, 2025 |
|
Joel Beatty |
Robert W. Baird |
$28.00 |
$23.09 |
21.3%
|
Catalyst Pharmaceuticals initiated with an Outperform at Baird
|
Feb 04, 2025 |
|
Randal Konik |
Jefferies |
$1.60 |
$1.68 |
-4.8%
|
Brilliant Earth downgraded to Hold from Buy at Jefferies
|
Feb 04, 2025 |
|
Sanjit Singh |
Morgan Stanley |
$95.00 |
$103.83 |
-8.5%
|
Palantir upgraded to Equal Weight from Underweight at Morgan Stanley
|
Feb 04, 2025 |
|
Brent Thill |
Jefferies |
$60.00 |
$103.83 |
-42.2%
|
Palantir price target raised to $60 from $28 at Jefferies
|
Feb 04, 2025 |
|
Leah Jordan |
Goldman Sachs |
$26.00 |
$20.25 |
28.4%
|
Albertsons reinstated with a Buy at Goldman Sachs
|
Feb 04, 2025 |
|
Eric Handler |
Roth Capital |
$3.25 |
$3.16 |
2.8%
|
AMC Entertainment upgraded to Neutral from Sell at Roth MKM
|
Feb 04, 2025 |
|
Andy Chen |
Wolfe Research |
$20.00 |
$13.70 |
46.0%
|
Oruka Therapeutics initiated with an Outperform at Wolfe Research
|
Feb 04, 2025 |
|
Andy Chen |
Wolfe Research |
$25.00 |
$16.66 |
50.1%
|
AnaptysBio initiated with an Outperform at Wolfe Research
|
Feb 03, 2025 |
|
Ruben Roy |
Stifel Nicolaus |
$140.00 |
$120.88 |
15.8%
|
Celestica resumed with a Buy at Stifel
|
Feb 03, 2025 |
|
Luke Sergott |
Barclays |
$58.00 |
$52.75 |
10.0%
|
Twist Bioscience price target raised to $58 from $52 at Barclays
|
Feb 03, 2025 |
|
Peter Osterland |
Truist Financial |
$32.00 |
$27.76 |
15.3%
|
These Analysts Cut Their Forecasts On Olin After Q4 Earnings
|
Feb 03, 2025 |
|
Betty Jiang |
Barclays |
$34.00 |
$25.56 |
33.0%
|
These Analysts Lower Their Forecasts On Murphy Oil After Downbeat Earnings
|
Feb 03, 2025 |
|
Josh Silverstein |
UBS |
$32.00 |
$25.56 |
25.2%
|
These Analysts Lower Their Forecasts On Murphy Oil After Downbeat Earnings
|
Feb 03, 2025 |
|
Roger Read |
Wells Fargo |
$31.00 |
$25.56 |
21.3%
|
These Analysts Lower Their Forecasts On Murphy Oil After Downbeat Earnings
|
Feb 03, 2025 |
|
Dana Telsey |
Telsey Advisory |
$83.00 |
$73.53 |
12.9%
|
Tapestry price target raised to $83 from $74 at Telsey Advisory
|
Feb 03, 2025 |
|
Greg McGinniss |
Scotiabank |
$73.00 |
$58.18 |
25.5%
|
Lineage price target lowered to $73 from $76 at Scotiabank
|
Feb 03, 2025 |
|
Phil Hardie |
Scotiabank |
$33.00 |
$21.53 |
53.3%
|
Brookfield Business Partners price target raised to $33 from $32 at Scotiabank
|
Feb 03, 2025 |
|
John Roberts |
Mizuho Securities |
$140.00 |
$111.99 |
25.0%
|
PPG price target lowered to $140 from $150 at Mizuho
|
Feb 03, 2025 |
|
Graig Suvannavejh |
Mizuho Securities |
$137.00 |
$107.43 |
27.5%
|
Axsome Therapeutics price target raised to $137 from $122 at Mizuho
|
Feb 03, 2025 |
|
David Toung |
Argus Research |
$450.00 |
$391.14 |
15.0%
|
Stryker price target raised to $450 from $410 at Argus
|
Feb 03, 2025 |
|
Heidi Hauch |
BNP Paribas |
$10.00 |
$10.54 |
-5.1%
|
XPLR Infrastructure upgraded to Neutral from Underperform at Exane BNP Paribas
|
Feb 03, 2025 |
|
John Eade |
Argus Research |
$250.00 |
$204.11 |
22.5%
|
GE Aerospace price target raised to $250 from $210 at Argus
|
Feb 03, 2025 |
|
Hamir Patel |
CIBC |
$63.00 |
$52.08 |
21.0%
|
Methanex price target raised to $63 from $59 at CIBC
|
Feb 03, 2025 |
|
Kenneth Lee |
RBC Capital |
$65.00 |
$54.55 |
19.2%
|
OneMain price target raised to $65 from $62 at RBC Capital
|
Feb 03, 2025 |
|
Stephen Laws |
Raymond James |
$15.00 |
$11.70 |
28.2%
|
Sunrise Realty price target lowered at Raymond James following stock offering
|
Feb 03, 2025 |
|
Michael Ciarmoli |
Truist Financial |
$410.00 |
$367.29 |
11.6%
|
RBC Bearings price target raised to $410 from $351 at Truist
|
Feb 03, 2025 |
|
Seth Basham |
Wedbush |
$80.00 |
$66.92 |
19.5%
|
Wedbush upgrades Tempur after FTC denied of blocking merger
|
Feb 03, 2025 |
|
David Motemaden |
Evercore ISI |
$123.00 |
$112.30 |
9.5%
|
Hartford Financial price target lowered to $123 from $125 at Evercore ISI
|
Feb 03, 2025 |
|
Daniel Ives |
Wedbush |
$150.00 |
$126.63 |
18.5%
|
Huron assumed with an Outperform at Wedbush
|
Feb 03, 2025 |
|
Daniel Ives |
Wedbush |
$9.00 |
$6.88 |
30.8%
|
CI&T assumed with an Outperform at Wedbush
|
Feb 03, 2025 |
|
Joon Lee |
Truist Financial |
$190.00 |
$107.43 |
76.9%
|
Axsome Therapeutics price target raised to $190 from $180 at Truist
|
Feb 03, 2025 |
|
Daniel Tamayo |
Raymond James |
$62.00 |
$52.51 |
18.1%
|
First Business Financial price target raised to $62 from $52 at Raymond James
|
Feb 03, 2025 |
|
John Dunn |
Evercore ISI |
$44.00 |
$39.37 |
11.8%
|
Federated Hermes price target raised to $44 from $42 at Evercore ISI
|
Feb 03, 2025 |
|
John McNulty |
BMO Capital |
$226.00 |
$183.34 |
23.3%
|
Avery Dennison price target lowered to $226 from $252 at BMO Capital
|
Feb 03, 2025 |
|
David Feaster |
Raymond James |
$71.00 |
$64.23 |
10.5%
|
Ameris Bancorp price target raised to $71 from $67 at Raymond James
|
Feb 03, 2025 |
|
Gary Nachman |
Raymond James |
$220.00 |
$190.14 |
15.7%
|
AbbVie price target raised to $220 from $218 at Raymond James
|
Feb 03, 2025 |
|
Rohit Kulkarni |
Roth Capital |
$32.00 |
$33.08 |
-3.3%
|
Pinterest price target lowered to $32 from $33 at Roth MKM
|
Feb 03, 2025 |
|
Rick Paterson |
Loop Capital Markets |
$115.00 |
$111.29 |
3.3%
|
UPS price target lowered to $115 from $120 at Loop Capital
|
Feb 03, 2025 |
|
Carlos De Alba |
Morgan Stanley |
$154.00 |
$131.30 |
17.3%
|
Nucor price target lowered to $154 from $166 at Morgan Stanley
|
Feb 03, 2025 |
|
Carlos De Alba |
Morgan Stanley |
$11.00 |
$9.74 |
12.9%
|
Cleveland-Cliffs price target lowered to $11 from $13 at Morgan Stanley
|
Feb 03, 2025 |
|
Vamil Divan |
Guggenheim |
$166.00 |
$151.87 |
9.3%
|
Johnson & Johnson price target raised to $166 from $162 at Guggenheim
|
Feb 03, 2025 |
|
Evan Seigerman |
BMO Capital |
$215.00 |
$190.14 |
13.1%
|
AbbVie price target raised to $215 from $208 at BMO Capital
|
Feb 03, 2025 |
|
Mark Astrachan |
Stifel Nicolaus |
$105.00 |
$93.44 |
12.4%
|
Elf Beauty price target lowered to $105 from $115 at Stifel
|
Feb 03, 2025 |
|
Luke Junk |
Robert W. Baird |
$31.00 |
$25.17 |
23.2%
|
Gentex price target lowered to $31 from $35 at Baird
|
Feb 03, 2025 |
|
Clark Lampen |
BTIG |
$59.00 |
$41.39 |
42.5%
|
DraftKings price target raised to $59 from $55 at BTIG
|
Feb 03, 2025 |
|
Joel Beatty |
Robert W. Baird |
$132.00 |
$107.43 |
22.9%
|
Axsome Therapeutics price target raised to $132 from $116 at Baird
|
Feb 03, 2025 |
|
Michael Bellisario |
Robert W. Baird |
$285.00 |
$290.46 |
-1.9%
|
Marriott price target raised to $285 from $264 at Baird
|
Feb 03, 2025 |
|
Nathan Jones |
Stifel Nicolaus |
$209.00 |
$215.70 |
-3.1%
|
Badger Meter price target raised to $209 from $208 at Stifel
|